Christopher A. Sullivan, M.D.
Clinical Interests
Head & Neck Surgical Oncology
Surgery of Thyroid and Parathyroid Glands
Salivary Gland Tumors
Within the Department of Otolaryngology, Dr. Sullivan subspecializes in head and neck oncologic surgery, surgery of the thyroid, parathyroid and salivary glands. He operates on squamous cell cancers of the upper aerodigestive tract, thyroid and parathyroid tumors as well as benign and malignant salivary gland tumors. He treats both adult and pediatric patients. His research interest is salivary gland tissue engineering for the treatment of disorders that cause xerostomia
Assistant Professor
Clinical Interest:
Head & Neck Surgical Oncology
Head and Neck Reconstruction
Education:
1987 B.A. (Classics) Dartmouth College, Hanover, New Hampshire
1993 M.D. George Washington University, Washington, D.C.
Postdoctoral Training
1994 Internship: General Surgery, Case Western Reserve University Hospitals of Cleveland, Cleveland, OH
1998 Residency: Otolaryngology Head and Neck Surgery, Case Western Reserve University Hospitals of Cleveland, Cleveland, OH
1999 Fellowship: Head and Neck Oncologic Surgery, Cranial Base Surgery, Head and Neck Reconstructive Surgery, Vanderbilt University Medical Center, Nashville, TN
Board Certification: American Board of Otolaryngology
Society Memberships:
American Medical Association
American Academy of Otolaryngology, Head and Neck Surgery
New England Otolaryngologic Society
Honors and Awards:
1987 John J. Zimmerman Award for Capital Fundraising Campaign
1987 Dartmouth College Alumni Fund Director’s Award
2004 Partners in Excellence Clinical Achievement Award
Recent Select Publications: Original Articles
1. Sullivan CA, Rader AE, Abdul-Karim FW, Abbass HA, Mohr, RM. Dose related tissue effects of the carbon dioxide and non-contact neodymium:yag lasers in the canine glottis. Laryngoscope . 1998;108(9);1284.
2. Sullivan CA, Masin JA, Maniglia AJ, Stepnick DW. Complications of rhytidectomy in an otolaryngology training program. Laryngoscope , 1999;109(2)198.
3. Day TA, Carr C, Zealear D, Burkey BB, Sullivan CA. Tongue replantation in an animal model. Microsurgery, 2000; 20(3)105(8).
4. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan CA, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel,cisplatin and 5-fluorouracil-based induction chemotherapy in patients with locally advanced carcinoma of the head and neck: the Dana Farber Cancer Institute Experience. Cancer, 2003; 97(2):412-8.
5. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L. Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatinum, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. Oncologist, 2003;8(1):35-44.
6. Sullivan CA, Haddad RI, Jaklitsch MT, Goguen LA, Posner MR, Tishler RB, Norris CM. Endoscopic Management of Hypopharyngeal Stenosis following Organ Sparing Therapy for Head and Neck Cancer. Laryngoscope 2004;114:1924-1931.
7. Posner MR, Haddad RI, Wirth LJ, Norris CM, Goguen LA, Mahadevan A, Sullivan CA, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin. Oncol. 2004(9)1-8